Perkembangan Imunoterapi untuk Kanker
Imunoterapi
DOI:
https://doi.org/10.55175/cdk.v45i8.743Keywords:
Imunoterapi, kanker, sistem imunAbstract
Imunoterapi untuk kanker ditujukan untuk memodulasi dan menggunakan sistem imun pasien dengan target sel kanker dibandingkan menggunakan modalitas terapi ekstrinsik. Imunoterapi untuk kanker ditujukan untuk mengaktivasi atau meningkatkan pengenalan oleh sistem imun dan penghancuran sel-sel kanker. Terdapat beberapa pendekatan imunoterapi seperti vaksin kanker, virus onkolitik, transfer sel adoptif, antibodi monoklonal penghambat CTLA-4, PD-1, dll. Beberapa jenis dari terapi tersebut telah disetujui oleh US FDA untuk terapi kanker.
Cancer immunotherapy means modulating and using patient’s immune system to target the cancer cells rather than using an extrinsic means of therapy. It is designed to activate or enhance the immune system’s recognition and killing of the cancer cells. Some immunotherapeutic approaches can be offered, such as cancer vaccine, oncolytic virus, adoptive cell transfer, monoclonal antibody blocking of cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), etc. Some have been approved by US FDA for cancer therapy.
Downloads
References
Morrissey KM, Yuraszeck TM, Li CC, Zhang Y, Kasichayanula S. Immunotherapy and novel combinations in oncology: Current landscape, challenges, and opportunities. Clin Transl Sci. 2016;9:89-104.
Li YS, Li FF, Jiang F, Lv XQ, Zhang RJ, Lu AP, et al. A mini-review for cancer immunotherapy: Molecular understanding of PD-1/PD-L1 pathway & translational blockade of immune checkpoints. Int J Mol Sci. 2016;17:1151.
Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: Harnessing potential synergies. Cancer Immunol Res. 2015;3(5):436-43.
Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012;62:309-35.
Jiang T, Zhou CC. The past, present and future of immunotherapy against tumor. Transl Lung Cancer Res. 2015;4(3):253-64.
Parish CR. Cancer immunotherapy: The past, the present and the future. Immunology and Cell Biology 2003;81:106-13.
Meiliana A, Dewi NM, Wijaya A. Cancer immunotherapy: A review. Indones Biomed J. 2016;8(1):1-20.
Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: The beginning of the end of cancer? BMC Medicine 2016;14:73.
Yuzhakova DV, Shirmanova MV, Sergeeva TF, Zagaynova EV, Lukyanov KA. Immunotherapy of cancer (review). CTM 2016;8(1):173-81.
Geresu MA, Sultan AF, Ahmed SK, Kassa GM. Immunotherapy against cancer: A comprehensive review. J Cancer Res Exp Oncol. 2016;8(2):15-25.
Guo CQ, Manjili MH, Subjeck JR, Sarkar D, Fisher PB, Wang XY. Therapeutic cancer vaccines: Past, present and future. Adv Cancer Res. 2013;119:421-75.
Graff JN, Chamberlain ED. Sipuleucel-T in the treatment of prostate cancer: An evidence-based review of its place in therapy. Core Evidence 2010;10:1-10.
Sipuleucel-T. Product information. Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM210031.pdf
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-22.
Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Sci. 2016;107:1373-9.
Talimogene laherparepvec. Product information. Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM469575.pdf
Andtbacka RHI, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780-8.
New Drugs. Talimogene laherparepvec. Aust Prescr. 2017;40:38-9.
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer 2012;12:252-64.
Ipilimumab. Product information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125377s073lbl.pdf
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23.
Pembrolizumab. Product information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s024lbl.pdf
Nivolumab. Product information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125554s034lbl.pdf
Anna LK. Imunoterapi untuk kanker paru kini tersedia di Indonesia. Kompas.com [Internet]. 2017 June 16 [cited 2017 Oct 30]. Available from: http://sains.kompas.com/read/2017/06/16/190300423/imunoterapi.untuk.kanker.paru.kini.tersedia.di.indonesia
Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823-33.
Huehls AM, Coupet TA, Sentman CL. Bispecific T cell engagers for cancer immunotherapy. Immunol Cell Biol. 2015;93(3):290-6.
Hoffman LM, Gore L. Blinatumomab, a bi-specific anti-CD19/CD3 BiTE® antibody for the treatment of acute lymphoblastic leukemia: Perspectives and current pediatric applications. Pediatric Oncology 2014;63(4):1-5.
Wu JJ, Fu JP, Zhang MZ, Liu DL. Blinatumomab: A bispesific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. Journal of Hematology & Oncology 2015;8:104.
Blinatumomab. Product information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125557lbl.pdf
Kantarjian H, Stein A, Gokbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836-47.
Perica K, Varela JC, Oelke M, Schneck J. Adoptive T cell immunotherapy for cancer. Rambam Maimonides Med J. 2015;6(1):1-9.
Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy. Nature Reviews Clinical Oncology 2016 doi: 10.1038/nrclinonc.2016.25.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 https://creativecommons.org/licenses/by-nc/4.0/
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
